These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 30091999

  • 1. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M, Hugues P, Desterke C, Telliam G, Sloma I, Souza LEB, Baykal S, Artus J, Griscelli F, Guerci A, Johnson-Ansah H, Foudi A, Bennaceur-Griscelli A, Turhan AG.
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R.
    Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
    [Abstract] [Full Text] [Related]

  • 5. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.
    Biochem Biophys Res Commun; 2016 Apr 15; 472(4):610-6. PubMed ID: 26966074
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, Martinelli G, Baccarani M, Ferrari S, Manfredini R.
    Blood; 2009 Dec 10; 114(25):5191-200. PubMed ID: 19855080
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation.
    Bhatia R, Munthe HA, Williams AD, Zhang F, Forman SJ, Slovak ML.
    Exp Hematol; 2000 Dec 10; 28(12):1401-12. PubMed ID: 11146162
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
    Moore S, Haylock DN, Lévesque JP, McDiarmid LA, Samels LM, To LB, Simmons PJ, Hughes TP.
    Blood; 1998 Oct 01; 92(7):2461-70. PubMed ID: 9746786
    [Abstract] [Full Text] [Related]

  • 16. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
    Chu S, McDonald T, Bhatia R.
    Leukemia; 2010 Apr 01; 24(4):779-87. PubMed ID: 20200561
    [Abstract] [Full Text] [Related]

  • 17. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L, Yu J, Chen R, Liu Y, Lou L, Wu Y, Huang L, Fan Y, Gao P, Huang M, Wu Y, Chen Y, Xu J.
    Clin Cancer Res; 2015 Feb 15; 21(4):833-43. PubMed ID: 25501124
    [Abstract] [Full Text] [Related]

  • 18. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
    Ly M, Rentas S, Vujovic A, Wong N, Moreira S, Xu J, Holzapfel N, Bhatia S, Tran D, Minden MD, Draper JS, Hope KJ.
    Cancer Res; 2019 Nov 15; 79(22):5799-5811. PubMed ID: 31519687
    [Abstract] [Full Text] [Related]

  • 19. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J.
    J Clin Invest; 2016 Oct 03; 126(10):3961-3980. PubMed ID: 27643437
    [Abstract] [Full Text] [Related]

  • 20. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, Chao TY, Yeh CT.
    Exp Cell Res; 2018 Sep 15; 370(2):519-530. PubMed ID: 30017934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.